LivaNova PLC ( (LIVN) ) has released its Q1 earnings. Here is a breakdown of the information LivaNova PLC presented to its investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
LivaNova PLC is a global medical technology company specializing in innovative solutions for neurological and cardiac conditions, with a strong presence in over 100 countries. In its first-quarter 2025 earnings report, LivaNova announced a significant revenue increase and updated its full-year guidance to reflect recent developments. The company reported a 7.4% increase in revenue on a reported basis, with a 10.4% organic growth, driven by strong performance in cardiopulmonary and neuromodulation segments. Despite a GAAP loss per share due to environmental liabilities, the adjusted earnings per share showed improvement. LivaNova also highlighted its progress in regulatory and clinical milestones, particularly in its obstructive sleep apnea program. Looking forward, LivaNova has raised its revenue growth expectations for 2025, indicating confidence in its operational performance and strategic initiatives.